Cara Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Director Susan Shiff was granted 6,000 stock options in Tvardi Therapeutics, Inc. as part of a standard equity compensation arrangement.
Director Sujal Shah was granted 6,000 stock options in Tvardi Therapeutics, Inc. as part of a standard equity compensation plan.
Director Wallace L. Hall Jr. was granted 6,000 stock options in Tvardi Therapeutics, Inc. with an exercise price of $2.78.
Director Michael S. Wyzga was granted 6,000 stock options in Tvardi Therapeutics, Inc. as part of a standard equity compensation arrangement.
Tvardi Therapeutics' Principal Accounting Officer, Stephen Paul O'Brien, was granted 15,000 employee stock options with an exercise price of $3.90, vesting over 48 months.
Tvardi Therapeutics' Chief Financial Officer, Avi Daniel Conn, was granted 45,000 employee stock options with an exercise price of $3.9 per share.
Tvardi Therapeutics' Chief Medical Officer, Dr. John Saewook Kauh, was granted 45,000 employee stock options.
Tvardi Therapeutics CEO Imran Nizamudin Alibhai was granted 115,000 employee stock options with a $3.9 exercise price, vesting over 48 months.
Tvardi Therapeutics, Inc. granted 4,000 employee stock options to its Principal Accounting Officer, Stephen Paul O'Brien, with an exercise price of $4.20.
Tvardi Therapeutics' Chief Medical Officer, Dr. John Saewook Kauh, was granted 17,500 employee stock options with a $4.2 exercise price.
Tvardi Therapeutics' Chief Financial Officer, Avi Daniel Conn, was granted 17,500 employee stock options with a $4.2 exercise price, vesting over four years.
Tvardi Therapeutics, Inc. CEO Imran Nizamudin Alibhai was granted 47,500 employee stock options with an exercise price of $4.2, vesting over four years.
Samuel David Tweardy, a Director and 10% owner of Tvardi Therapeutics, Inc., reported a change in the form of his beneficial ownership of 315,658 common shares, stemming from a trustee resignation.
Wallace L. Hall Jr., a director of Tvardi Therapeutics, files an amended Form 4 to correct an initial error in the transaction code related to the acquisition of common stock following the merger with Legacy Tvardi.
Shaheen Wirk, a director of Tvardi Therapeutics, reports acquiring shares of common stock following the merger of Merger Sub with Legacy Tvardi.
Jeffrey Leroy Larson, SVP of Research & Development at Tvardi Therapeutics, acquired 10,820 stock options on April 17, 2025.
Stephen Paul O'Brien, Principal Accounting Officer of Tvardi Therapeutics, received employee stock options for 7,213 shares on April 17, 2025, vesting over four years.
Yixin Chen, VP at Tvardi Therapeutics, reports acquisition of stock options.
Avi Daniel Conn, CFO of Tvardi Therapeutics, acquires 43,547 employee stock options at an exercise price of $17.04.
Dr. John Saewook Kauh, Chief Medical Officer of Tvardi Therapeutics, was granted stock options to purchase 36,210 shares of common stock.
Imran Nizamudin Alibhai, CEO of Tvardi Therapeutics, receives stock options for 182,320 shares.
Susan Shiff, a director at Tvardi Therapeutics, acquired stock options for 12,000 shares on April 17, 2025.
Director Shaheen Wirk acquired 12,000 stock options in Tvardi Therapeutics, Inc. on April 17, 2025.
Michael S. Wyzga, a director at Tvardi Therapeutics, acquired 12,000 stock options on April 17, 2025, according to a Form 4 filing with the SEC.
Director Cynthia Smith of Tvardi Therapeutics, Inc. was granted stock options to purchase 12,000 shares of common stock.
Director Sujal Shah of Tvardi Therapeutics acquires stock options exercisable for 12,000 shares of common stock.
Director Wallace L Hall Jr. acquired 12,000 stock options in Tvardi Therapeutics on April 17, 2025, according to a Form 4 filing.
Stephen Paul O'Brien, Principal Accounting Officer of Tvardi Therapeutics, acquires stock options as part of a merger agreement.
Wallace L Hall Jr., a director of Tvardi Therapeutics, acquired shares of common stock through a merger and conversion of preferred stock and convertible notes.
Chief Medical Officer John Saewook Kauh M.D. reports acquisition of stock options in Tvardi Therapeutics following a merger.